SIGLEC1 and viral infectious disease: The good diagnostic performance of CD169 as a biomarker of acute viral disease so far, seems to be promising in both viral epidemics where high sensitivity is needed (“rule-out-approach”), and in non-epidemic scenarios where high specificity is required (“rule-in approach”).